Pfizer and BioNTech announced on Friday that its COVID-19 vaccine could be reworked in “approximately 100 days” to counter a new variant of the CCP virus that may be able to penetrate through vaccines.

The U.S.-based pharmaceutical company said in a statement obtained by news agency Reuters it expects more data on B.1.1.529, the new variant of the virus that was dubbed “Omicron” by the World Health Organization (WHO), to determine whether its vaccine would have to be reworked.

“We understand the concern of experts and have immediately initiated investigations on variant B.1.1.529,” BioNTech said in the statement when asked to comment.